Keene & Associates Inc. Sells 534 Shares of Pfizer Inc. (NYSE:PFE)

Keene & Associates Inc. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 0.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,687 shares of the biopharmaceutical company’s stock after selling 534 shares during the period. Pfizer makes up approximately 2.5% of Keene & Associates Inc.’s holdings, making the stock its 23rd biggest holding. Keene & Associates Inc.’s holdings in Pfizer were worth $3,125,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in Pfizer during the second quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC increased its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer during the second quarter valued at approximately $34,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, September 9th. Finally, UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

PFE opened at $29.27 on Monday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The business’s fifty day simple moving average is $29.21 and its 200-day simple moving average is $28.13. The company has a market capitalization of $165.86 billion, a price-to-earnings ratio of -487.83, a PEG ratio of 1.04 and a beta of 0.68. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.42.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the firm posted $0.67 EPS. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.74%. Pfizer’s dividend payout ratio is currently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.